Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 12/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809602 | 0.92 | BRD4 (0.41) | CREBBPBRD4ROCK2ROCK1CDC42BPB | |
| SCHEMBL17806246 | 0.85 | CREBBP (0.37) | CREBBPBRD4ROCK2ROCK1CDC42BPB | |
| SCHEMBL17806240 | 0.79 | CREBBP (0.38) | CREBBPBRD4ROCK2ROCK1CDC42BPB | |
| SCHEMBL17809615 | 0.76 | BRD4 (0.38) | CREBBPBRD4ROCK2ROCK1CDC42BPB | |
| SCHEMBL17794805 | 0.73 | BRD4 (0.43) | CREBBPBRD4ROCK2ROCK1CDC42BPB | |
| SCHEMBL17809572 | 0.73 | CREBBP (0.50) | CREBBPBRD4EP300 | |
| SCHEMBL17809532 | 0.72 | GRM5 (0.39) | CREBBPBRD4ROCK2ROCK1CDC42BPB | |
| SCHEMBL17785761 | 0.72 | GPR119 (0.44) | CREBBPBRD4LRRK2 | |
| SCHEMBL23055771 | 0.71 | GRM5 (0.45) | CREBBPBRD4 | |
| SCHEMBL17785702 | 0.71 | AURKA (0.40) | CREBBPBRD4ROCK2ROCK1CDC42BPB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2016086200-A9 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CREBBP 6/4885BRD4 11/4885ROCK2 2944/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CREBBP 6/4885BRD4 11/4885ROCK2 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.